Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01291511 · ClinicalTrials.gov registry record · Phase 3
Relapse Prevention Study in Patients With Schizophrenia
A Phase 3 study of Schizophrenia, sponsored by Vanda Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 635
- Enrollment target
- 20
- Study locations
NCT01291511 is a Phase 3 study of Schizophrenia that has completed, run by Vanda Pharmaceuticals. The registered enrollment target is 635 participants, above the 217-participant average among 315 other Schizophrenia trials with a reported enrollment target (193% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT01291511, a Phase 3 study of Schizophrenia, has completed, sponsored by Vanda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 635 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether Iloperidone is effective in the prevention of relapse in patients with schizophrenia
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Iloperidone
Study Locations (20)
California
- Vanda Investigative Site - Anaheim
- Vanda Investigative Site - Bellflower
- Vanda Investigative Site - Costa Mesa
- Vanda Investigative Site - Escondido
- Vanda Investigative Site - La Habra
- Vanda Investigative Site - Oceanside
- Vanda Investigative Site - Orange
- Vanda Investigative Site - Pico Rivera
- Vanda Investigative Site - Riverside
- Vanda Investigative Site - San Diego
- Vanda Investigative Site - San Diego
- Vanda Investigative Site - San Diego
- Vanda Investigative Site - Santa Ana
Florida
- Vanda Investigative Site - Melbourne
- Vanda Investigative Site - Miami
- Vanda Investigative Site - Oakland Park
Georgia
- Vanda Investigative Site - Atlanta
- Vanda Investigative Site - Atlanta
Missouri
- Vanda Investigative Site - St Louis
New Hampshire
- Vanda Investigative Site - Nashua
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 635 participants |
| Start Date | 2011-02 |
| Est. Completion | 2015-03 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01291511
The ClinicalTrials.gov registry entry for NCT01291511 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 635 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 217-participant average among 315 other Schizophrenia trials with a reported enrollment target (193% higher). The listed sponsor is Vanda Pharmaceuticals, which has 68 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Schizophrenia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01291511 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT01291511 about?
NCT01291511 is a clinical study titled "Relapse Prevention Study in Patients With Schizophrenia". The purpose of this study is to determine whether Iloperidone is effective in the prevention of relapse in patients with schizophrenia
What is the current status of trial NCT01291511?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 635 participants. The study started on 2011-02. Estimated completion is 2015-03.
What conditions does trial NCT01291511 study?
This clinical trial studies the following conditions: Schizophrenia.
What interventions are being tested in trial NCT01291511?
The interventions under investigation include: Placebo (DRUG), Iloperidone (DRUG).
Who is sponsoring clinical trial NCT01291511?
This trial is sponsored by Vanda Pharmaceuticals, which has 68 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01291511 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Missouri, New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Schizophrenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
RECRUITING · Phase 3
-
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
RECRUITING · Phase 3
-
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
RECRUITING · Phase 3
-
Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
RECRUITING · Phase 3
-
A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.